Thymic tumors comprise a heterogeneous group of neoplasms with a wide spectrum of
clinical presentations. The evolution of the disease is often unpredictable, ranging from an …

Purpose Thymic malignancies, comprising thymoma and thymic carcinoma, are rare.
Consequently, optimal chemotherapy for advanced thymic malignancies remains …

Purpose The purpose of this study was to evaluate the impact of carboplatin and paclitaxel
in patients with advanced previously untreated thymoma and thymic carcinoma. Patients …

In this largest phase II trial with advanced thymic carcinoma (TC), carboplatin and paclitaxel
(CbP) showed promising efficacy in advanced TC when compared with anthracycline-based …

Masses in the anterior mediastinum can be neoplasms (eg, thymomas, thymic carcinomas,
or lung metastases) or non-neoplastic conditions (eg, intrathoracic goiter). Thymomas are …

BACKGROUND: There are few data on outcomes after surgical treatment for recurrent
thymic tumors. The aim of this study is to analyze and compare long-term outcomes of …

Thymic epithelial tumors (TETs) are a relatively rare type of thoracic tumor, accounting for
less than 1% of all tumors. The incidence of TETs is about 3.93/10000 in China, slightly …

Abstract Introduction Thymic epithelial tumors (TETs) including thymoma and thymic
carcinoma are rare tumors with little data available to guide treatment. Immunotherapy with …

Background Immunotherapy has demonstrated good efficacy and survival outcomes in solid
tumours. However, efficacy data for immune checkpoint inhibitors (ICIs) in advanced thymic …

Introduction: Thymic carcinoma is a rare epithelial neoplasm that tends to be aggressive and
metastasize widely. The optimal chemotherapy for unresectable advanced thymic carcinoma …